Roche agreed to acquire PathAI for up to $1.05 billion to expand its digital pathology capabilities and strengthen AI-powered diagnostic workflows. Under the terms announced, Roche will pay $750 million upfront and up to $300 million in additional milestone payments, with closing expected in the second half of 2026 subject to regulatory approvals and antitrust review. Roche said the deal will provide access to PathAI’s Image Management System (IMS), aimed at integrating image analysis with lab workflow. The companies also cited their collaboration history beginning in 2021 and expanded in 2024, including development of AI-enabled companion diagnostic algorithms. The acquisition signals continued pharma investment in computational diagnostics infrastructure as data integration and biopsy scoring tools increasingly influence clinical trial operations and biomarker development.